Trans-arterial chemo-embolization with doxorubicin is associated with a rare risk of delayed febrile neutropenia in patients with hepatocellular carcinoma.
Does conventional trans-arterial chemo-embolization (C-TACE) with doxorubicin cause delayed febrile neutropenia in patients with hepatocellular carcinoma?
Conventional trans-arterial chemo-embolization (C-TACE) with doxorubicin may be associated with a rare complication of delayed febrile neutropenia, warranting vigilance and monitoring.
Absolute Event Rate: 0% vs 0%
Background: Trans-arterial chemo-embolization (TACE) using doxorubicin is an established treatment option for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients. In this case report, we describe a rare occurrence of delayed febrile neutropenia following conventional TACE (C-TACE) with doxorubicin. This complication, while recognized with systemic doxorubicin, is rarely documented in the context of C-TACE. Case presentation: We present a 53-year-old Bangladeshi man with hepatitis B-related HCC who developed febrile neutropenia two weeks following C-TACE with doxorubicin. Indeed, previous C-TACE procedures had also resulted in similar neutropenic episodes, which pointed to the association of C-TACE with doxorubicin and neutropenia. Conclusions: The case brings attention and vigilance to the monitoring for neutropenia in patients receiving C-TACE with doxorubicin, an association rarely currently documented in the literature. Further studies are needed to assess its prevalence and identify risk factors and management strategies for this complication.
Hajmusa et al. (Thu,) reported a other. Trans-arterial chemo-embolization with doxorubicin is associated with a rare risk of delayed febrile neutropenia in patients with hepatocellular carcinoma.